GROWTH HORMONE AXIS RESEARCH / FAQ
Questions From the Study Record
Direct, citation-anchored answers to the questions readers most often bring to CJC-1295, ipamorelin, and MOTS-c.
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) — the natural signal that tells the pituitary gland to release growth hormone. Four amino-acid substitutions make it resistant to the enzymes that quickly break down native GHRH, and in its "DAC" form it also binds covalently to serum albumin, extending its effect from minutes to days. It has never been approved as a medicine anywhere; the human data behind it come from a small number of pharmacokinetic studies, and confirmation of its identity in circulation comes from a laboratory analysis of a seized black-market preparation [2][4].
What does CJC-1295 do?
In human pharmacokinetic studies, CJC-1295 produced dose-dependent 2- to 10-fold increases in growth hormone sustained for 6 or more days after a single dose, and 1.5- to 3-fold increases in IGF-1 sustained for 9-11 days, with repeated dosing keeping IGF-1 elevated for up to 28 days [4]. Separately, it caused measurable, reproducible shifts in several serum proteins that correlated with IGF-1 levels, suggesting candidate biomarkers of GH-axis activation [3]. Notably, this sustained stimulation did not disrupt the body's normal pulsatile pattern of GH release [5].
Is CJC-1295 safe?
CJC-1295 is not approved by the FDA or any other regulator, and its safety has not been established in any large or long-term human trial — the available human data are limited to small pharmacokinetic studies. Documented, mechanism-based cautions include sustained IGF-1 elevation (linked epidemiologically to a modestly higher cancer risk at the population level), fluid retention from GH's effect on the kidneys, and effects on insulin sensitivity. Regulators flagged immunogenicity concerns for this compound class in 2024 briefing materials. This is a summary of documented research cautions, not a safety judgment for any individual.
How much CJC-1295 should I take?
This desk does not answer that question, because CJC-1295 is not approved for human use and no dosing recommendation exists for it in any regulatory or clinical guideline. What can be reported is what specific research protocols used: published pharmacokinetic studies administered single subcutaneous doses of 30 or 60 micrograms/kg to healthy adults under controlled, monitored conditions [4]. That is a description of a study design, not a recommendation, and it does not account for the very different exposure profile of the DAC versus no-DAC forms.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide that activates the ghrelin receptor (GHS-R1a) to trigger a pulse of growth hormone release from the pituitary gland. Its defining pharmacological feature, established in its 1998 founding characterization, is that it does this without meaningfully raising ACTH or cortisol — hormones that older compounds in its class tend to elevate alongside GH — even at doses more than 200-fold above its GH-releasing threshold [11]. It has never been approved as a medicine; it is sold and studied only as a research compound.
What does ipamorelin do for you?
In its founding pharmacology, ipamorelin released growth hormone potently across rat pituitary cells, rats, and swine, at a potency broadly comparable to the older compound GHRP-6 [11]. In healthy human volunteers, a pharmacokinetic study found it produces a single, discrete GH pulse peaking about 40 minutes after dosing, with a terminal half-life of roughly 2 hours [9]. In its one completed human efficacy trial — a Phase 2 study in surgical patients — ipamorelin numerically shortened time to first tolerated meal, but the difference from placebo did not reach statistical significance [8]. This desk reports that result directly rather than minimizing it.
What is ipamorelin peptide?
Chemically, ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2 — a sequence built with unusual amino acids specifically chosen to resist enzymatic breakdown. It was derived from an earlier growth-hormone-releasing peptide, GHRP-1, by removing a central two-amino-acid segment, a modification that sharpened its receptor selectivity. It is classified as a growth hormone secretagogue, distinct from GHRH analogs like CJC-1295 because it acts on a different receptor (the ghrelin receptor) to reach the same downstream hormone [11].
What are the risks of ipamorelin?
Documented, mechanism-based cautions for ipamorelin include a theoretical cancer-risk concern tied to GH-driven IGF-1 elevation; a direct insulin-releasing effect on pancreatic tissue observed in rat studies, creating unpredictable glycemic impact particularly for people with existing glucose dysregulation; and a class-level cardiovascular caution — a 28-day preclinical safety study of a different ghrelin-receptor agonist (not ipamorelin itself) found dose-dependent heart-muscle damage in rats [7]. No long-duration cardiovascular study of ipamorelin itself exists in any species. Beyond mechanism, research-grade ipamorelin from unregulated suppliers carries no pharmaceutical quality assurance for purity or identity.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that activates AMP-activated protein kinase (AMPK), a cellular energy sensor, primarily by inhibiting the folate cycle and de novo purine biosynthesis [17]. In mouse studies, this translated into improved treadmill running capacity, grip strength, and gait in aged animals [16], and prevention of skeletal muscle atrophy alongside enhanced muscle glucose uptake via a newly identified direct binding target, casein kinase 2 (CK2) [13]. Almost all of this evidence comes from cells and rodents; there is no completed human interventional trial of MOTS-c.
What are the negative side effects of MOTS-c?
Because no completed human interventional trial of MOTS-c exists, there is no clinical side-effect record to report, and this desk does not fabricate one. The documented cautions are structural: no measured human pharmacokinetics exist, rodent-study doses cannot be extrapolated to people, the strongest human data come from a single 94-patient observational cohort rather than a dosing trial [14], and a pro-diabetogenic mitochondrial DNA variant documented in the wider literature suggests effects may not be uniform across populations. Research-grade MOTS-c from unregulated suppliers also carries no pharmaceutical purity or identity assurance.
Is MOTS-c legal to buy?
MOTS-c is not approved by the FDA or any other regulatory body for human use, and it is sold only as a research chemical for laboratory use. It is also treated as a prohibited substance in elite sport by major anti-doping authorities under hormone- and metabolic-modulator categories. This desk does not address purchasing, sourcing, or legal questions around specific suppliers; it summarizes only the published research record.
How often do you inject MOTS-c?
This desk does not answer that question, because no completed human interventional trial of MOTS-c has established a dosing schedule for people. The published rodent research uses a range of repeated-dosing protocols — for example, daily dosing over one to several weeks in mouse muscle and performance studies [13][16] — but rodent protocol design does not translate into a human dosing schedule, and this site reports research findings only, never a recommendation.